Kwang Dong’s targeted therapy Afinitor challenges to patent

Kwang Dong Pharmaceutical started to develop a first generic of ‘Afinitor(generic name: everolimus),’ a Novartis’ targeted therapy.

Used to treat diseases such as breast cancer and renal cancer, Afinitor is recording annually KRW 15 billion sales.

On the 28th, the Ministry of Food and Drug Safety(MFDS) approved a bioequivalence test plan of everolimus 10mg filed by Kwang Dong Pharmaceutical.